Company / Cash per Share
Celldex Therapeutics, Inc. Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$0.43
FY2025
5-year range
$0.43 / $0.84
FY2021-FY2025
Trend
+1.5%
vs FY2024
Sector context
#141 of 147
Health Care
What the data says
Among 147 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 4% for cash per share. Cash per Share returned to growth in FY2025 after 4 years of decline, reaching $0.43.
Based on SEC 10-K filings.
0.43 in FY2025 with a 5-year CAGR of -17.1%.
Declined from $0.62 to $0.43 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -11.4%
- 5-Year CAGR
- -17.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 147This company $0.43 Sector average $27.42
▼
-98.4% below sector average
Key checks
Key Insights
- In FY2025, cash per share increased 1.5% year-over-year.
- Ranks #141 out of 147 companies in the Health Care sector.
- Peak cash per share was recorded in FY2018.
- Lowest cash per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.43 | +1.5% |
| FY2024 | $0.43 | -31.4% |
| FY2023 | $0.62 | -0.1% |
| FY2022 | $0.62 | -25.6% |
| FY2021 | $0.84 | -24.3% |
| FY2020 | $1.11 | +67.3% |
| FY2019 | $0.66 | -85.6% |
| FY2018 | $4.60 | +1275.4% |
| FY2017 | $0.33 | -5.1% |
| FY2016 | $0.35 | -51.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026